SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the announcement of a $9.7 billion AI cloud services contract with Microsoft, including a substantial prepayment. The community is buzzing about the potential impact of this deal, which involves providing access to NVIDIA GB300 GPUs, and speculating on whether this positions IREN as a major player in AI infrastructure. Some traders are debating whether to take profits, while others are eagerly anticipating further gains and potential deals.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending following news of a ~$5.5B lease agreement with Amazon Web Services for AI workloads, despite reporting slightly lower than expected earnings. The community is buzzing about the significance of this deal and future contracts, drawing comparisons to similar deals by competitors in the data center and AI space. Bullish sentiment is strong, with some anticipating significant gains in the near future.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float, with traders actively discussing its potential for a significant upward move. Community members are pointing to the stock's history of past runs and are watching for a break above key resistance levels. Some traders are expressing caution, suggesting the move may be a pump and dump.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending following news of its acquisition by Kimberly-Clark ($KMB) for $48.7 billion in cash and stock, sparking a surge in KVUE shares and a drop in KMB's. Community discussions revolve around the deal's value for shareholders, potential gains, and calculations of the merger's impact on both stocks. Investor sentiment also considers concerns over Tylenol lawsuits and their broader effect on Kenvue's valuation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant regulatory update concerning its Huntington's disease treatment, AMT-130. The FDA's revised stance on the data requirements for approval has sparked community debate about the future of the drug and the company's strategy. Discussions also include speculation about potential buyouts and the implications for the broader biotech sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors discuss the company's potential revenue growth following recent earnings and future projections, especially the possibility of reaching $1 billion in 2026. The community is focused on whether upcoming catalysts, such as the potential launch of a new dosing regimen in 2027 and commercialization outside the US, will drive the stock towards a $10 billion market cap. Some traders are speculating on a potential buyout and how Neuraxpharm may factor into future decisions.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with discussions focused on whether the company can justify its high valuation amidst AI sector growth. Community members are debating potential catalysts like new contracts and a possible stock split, while some express concern about the stock's high P/E ratio and potential for a post-earnings dip. The company's positioning in government and commercial sectors, along with its AI capabilities, remains a key talking point.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark's stock is trending following news of its agreement to acquire Kenvue in a deal valued at $48.7 billion, triggering mixed reactions from the community. While some investors see long-term value and free cash flow potential, others express concern over potential lawsuits tied to Kenvue and the overall deal terms, contributing to active debate.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing volatility, sparking intense debate within the community about its future prospects and potential for recovery. Discussions range from accusations of market manipulation and frustration over stagnant price action despite broader market gains, to expressions of continued conviction and strategic accumulation. Sentiment is divided between those anticipating further declines and those who believe Jasmy is poised for a significant upswing, particularly with potential developments in Japan's digital landscape.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as the community grapples with the aftermath of a recent lawsuit against a former FDA official and his subsequent resignation, with shareholders debating potential buyout scenarios and the impact on share value. Community members are actively discussing the lawsuit's allegations of bribery and defamation and also earnings call, alongside speculation about the company's future direction and potential for a buyout. The conversations highlight the stock's volatility and the community's intense focus on corporate actions and external influences.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TTM Technologies (TTMI) Surpasses Q3 Earnings and Revenue Estimates

TTM (TTMI) delivered earnings and revenue surprises of +9.84% and +5.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

TTMI Set to Report Q3 Results: What's in the Cards for the Stock?

TTM Technologies' third-quarter 2025 performance is likely to have benefited from Aerospace and Defense strength amid softer bookings momentum.

New Strong Buy Stocks for September 25th

SITE, TTMI, PGY, KT and GLW have been added to the Zacks Rank #1 (Strong Buy) List on September 25, 2025.

Best Value Stocks to Buy for September 11th

FFBC, STNE and TTMI made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 11, 2025.

Wall Street Analysts Believe TTM (TTMI) Could Rally 27.33%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 27.3% in TTM (TTMI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TTM (TTMI) is an Incredible Growth Stock: 3 Reasons Why 

TTM (TTMI) possesses solid growth attributes, which could help it handily outperform the market.

New Strong Buy Stocks for August 22nd

GTX, KGS, E, MSBHF and TTMI have been added to the Zacks Rank #1 (Strong Buy) List on August 22, 2025.

3 Reasons Growth Investors Will Love TTM (TTMI)

TTM (TTMI) Upgraded to Strong Buy: What Does It Mean for the Stock?

TTM (TTMI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stock to Buy for August 6th

TTMI, HWM and MTZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 6, 2025.

TTM Technologies, Inc. engages in the manufacture and sale of printed circuit boards and backplane assemblies. It operates through the Printed Circuit Board and RF&S Components segments. The Printed Circuit Board segment consists of fifteen domestic PCB and sub-system plants, five PCB fabrication plants in China, and one in Canada. The RF&S Components segment consists of one domestic RF component plant and one RF component plant in China. The company offers products such as backplanes, system integration, chassis assemblies, integrated circuit substrates and chips, and engineering services. The company was founded on March 20, 1978 and is headquartered in Santa Ana, CA.

TTM Technologies Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

TTMI
TTM Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TTMI News

TTMITTM Technologies Inc